myosin binding protein C2Genealiases: MYBPC · MYBPCF · fsMyBP-C
Q-omics provides the consensus-scored MYBPC2 profile across patient tissues and cancer cell-line models. MYBPC2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYBPC2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, MYBPC2 protein abundance shows 19,482 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where MYBPC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYBPC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYBPC2 survival associations across molecular data types. MYBPC2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYBPC2 RNA expression–survival associations across cancer types. High MYBPC2 expression shows unfavorable associations in KIRC, LGG, HNSC and LUSC, but favorable associations in CESC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYBPC2 RNA expression.
This table summarizes MYBPC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYBPC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYBPC2 shows lower tumor expression in COAD, HNSC and KICH and higher tumor expression in LUAD, UCEC and KIRP. The COAD box plot shows higher MYBPC2 RNA expression in normal versus tumor tissue (log2 FC = −0.392, t-test p = .001).
This table shows molecular features associated with MYBPC2 in patient tissues and cancer cell lines. In patient samples, MYBPC2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYBPC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
